Platelet-rich plasma effective remedy for dry eye

Article

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Autologous platelet-rich plasma (PRP) is a very effective treatment for severe dry eye symptoms, according to the results of a study published in the March issue of Ophthalmic Research.

Jorge Alio and colleagues from the Instituto Oftalmologico de Alicante and the Universidad Migul Hernandez, Alicante, Spain, treated 18 consecutive dry eye patients with topical PRP. The researchers were looking for the disappearance of subjective symptoms, increases in best corrected visual acuity (BCVA), tear meniscus, tear break-up time and decreases in inflammation and fluorescein staining. Improvements in impression cytology were also measured.

At one-month follow-up, 89% of subjects demonstrated a significant improvement in symptoms and 28% improved by at least one line of BCVA. A significant improvement in lachrymal meniscus and conjunctival hyperaemia, and a decrease or disappearance of corneal fluorescein staining was observed. Meanwhile, impression cytology revealed a significant increase in conjunctival goblet cells.

The authors of the study conclude that autologous PRP is a very effective treatment for severe dry eye symptoms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.